Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUAN C GARZA

Allopathic & Osteopathic Physicians Family Medicine

NPI
1669449971
CMS profile
165973
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$462.87

34 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $432.88 33
Education $29.99 1

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUAN C GARZA

NPI 1669449971 · CMS profile ID 165973

Allopathic & Osteopathic Physicians / Family Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669449971?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUAN C GARZA, NPI 1669449971, CMS profile ID 165973. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669449971?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JUAN C GARZA, NPI 1669449971, CMS profile ID 165973. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669449971?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JUAN C GARZA, NPI 1669449971, CMS profile ID 165973, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1669449971?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

34 matching records · $462.87 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 34 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–34 of 34.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan, Inc. $9.0612/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723766867 CMS
AstraZeneca Pharmaceuticals LP $13.0411/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736132441 CMS
Novo Nordisk Inc $15.3010/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744944913 CMS
Novo Nordisk Inc $19.4110/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744930581 CMS
Novo Nordisk Inc $14.2409/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744917249 CMS
Novo Nordisk Inc $1.9109/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744917251 CMS
Allergan, Inc. $21.6809/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723766863 CMS
Allergan, Inc. $10.0909/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723766865 CMS
AstraZeneca Pharmaceuticals LP $17.2909/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736173379 CMS
Novo Nordisk Inc $12.0409/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744898599 CMS
Novo Nordisk Inc $13.3408/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744847389 CMS
Allergan, Inc. $13.5008/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723766861 CMS
PFIZER INC. $6.1708/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743758333 CMS
Teva Pharmaceuticals USA, Inc. $15.5507/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749457177 CMS
AstraZeneca Pharmaceuticals LP $14.6406/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735810801 CMS
AstraZeneca Pharmaceuticals LP $13.0806/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735815347 CMS
Merck Sharp & Dohme Corporation $13.1806/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747724193 CMS
Allergan, Inc. $29.9905/20/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723766859 CMS
Novo Nordisk Inc $14.3005/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744716401 CMS
Novo Nordisk Inc $9.3704/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744671771 CMS
Allergan, Inc. $22.9304/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723766857 CMS
Novo Nordisk Inc $15.9804/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744663611 CMS
Genentech USA, Inc. $15.2103/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743038515 CMS
PFIZER INC. $9.5702/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743681351 CMS
PFIZER INC. $6.6602/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743681205 CMS
Allergan, Inc. $2.4102/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723766855 CMS
Amarin Pharma Inc. $14.2802/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739939509 CMS
Novo Nordisk Inc $9.8702/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744588075 CMS
PFIZER INC. $1.3902/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743681209 CMS
AstraZeneca Pharmaceuticals LP $13.9002/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735953161 CMS
Allergan, Inc. $12.6701/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723766853 CMS
AstraZeneca Pharmaceuticals LP $39.2401/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736299499 CMS
PFIZER INC. $6.4501/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743659613 CMS
Novo Nordisk Inc $15.1301/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744577705 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $697.42 45
PY2020 $462.87 34
PY2021 $606.41 45
PY2022 $1,514.63 68
PY2023 $1,566.78 94
PY2024 $1,681.91 93
PY2025 $1,387.30 78

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $43,373.43 14
PY2024 Principal investigator $171,802.76 70
PY2023 Recipient $23,812.92 7
PY2023 Principal investigator $383,116.06 124
PY2022 Principal investigator $624,521.08 179
PY2021 Principal investigator $663,885.83 360
PY2020 Principal investigator $248,213.43 166
PY2019 Principal investigator $403,386.63 210

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

70 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $1,352.60 12/31/2024 Non-covered Recipient Entity
VIP Trials
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na ve Adults No dispute reported 06/30/2026 1136436566
Principal investigator 1 Novo Nordisk AS $1,585.99 10/31/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1096815954
Principal investigator 1 Novo Nordisk AS $5,311.14 09/20/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1096841701
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,023.60 08/19/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150459
Principal investigator 1 Alnylam Pharmaceuticals Inc. $16,613.70 08/19/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150461
Principal investigator 1 Novo Nordisk AS $23.06 08/02/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1096868375
Principal investigator 1 Novo Nordisk AS $23.06 07/30/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1096856802
Principal investigator 1 Novo Nordisk AS $23.06 07/23/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1096752860
Principal investigator 1 Novo Nordisk AS $1,279.80 07/22/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1096832134
Principal investigator 1 Biogen, Inc. $17,375.50 06/28/2024 Non-covered Recipient Entity
Vip Trials
A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS) No dispute reported 06/30/2026 1104838174
Principal investigator 1 Novo Nordisk AS $853.20 06/21/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1096729814
Principal investigator 1 Novo Nordisk AS $6,180.79 06/10/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1096831243
Principal investigator 1 Novo Nordisk AS $962.50 05/24/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1096780053
Principal investigator 1 Novo Nordisk AS $2,250.00 05/24/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1096831251
Principal investigator 1 Novo Nordisk AS $10,142.63 04/30/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1096828015
Principal investigator 1 Alnylam Pharmaceuticals Inc. $450.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150419
Principal investigator 1 Alnylam Pharmaceuticals Inc. $26.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150421
Principal investigator 1 Alnylam Pharmaceuticals Inc. $125.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150423
Principal investigator 1 Alnylam Pharmaceuticals Inc. $75.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150425
Principal investigator 1 Alnylam Pharmaceuticals Inc. $520.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150427
Principal investigator 1 Alnylam Pharmaceuticals Inc. $50.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150429
Principal investigator 1 Alnylam Pharmaceuticals Inc. $36.20 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150431
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,125.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $678.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150435
Principal investigator 1 Alnylam Pharmaceuticals Inc. $732.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150437
Principal investigator 1 Alnylam Pharmaceuticals Inc. $12,690.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150439
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150441
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150443
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,985.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150445
Principal investigator 1 Alnylam Pharmaceuticals Inc. $504.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150447
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,000.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150449
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,985.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $450.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150453
Principal investigator 1 Alnylam Pharmaceuticals Inc. $125.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150455
Principal investigator 1 Alnylam Pharmaceuticals Inc. $26.00 04/05/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150457
Principal investigator 1 Novo Nordisk AS $23.06 03/21/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1096871751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,985.00 03/15/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150249
Principal investigator 1 Alnylam Pharmaceuticals Inc. $50.00 03/15/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150251
Principal investigator 1 Alnylam Pharmaceuticals Inc. $26.00 03/15/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150253
Principal investigator 1 Alnylam Pharmaceuticals Inc. $125.00 03/15/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150255
Principal investigator 1 Alnylam Pharmaceuticals Inc. $75.00 03/15/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150257
Principal investigator 1 Novo Nordisk AS $853.20 02/23/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1096832787
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,950.00 02/16/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $200.00 02/16/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150261
Principal investigator 1 Alnylam Pharmaceuticals Inc. $945.00 02/16/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150263
Principal investigator 1 Alnylam Pharmaceuticals Inc. $450.00 02/16/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150265
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 02/16/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150267
Principal investigator 1 Alnylam Pharmaceuticals Inc. $750.00 02/16/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150269
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,250.00 02/16/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150271
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 02/16/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150273
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,205.00 02/16/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150275
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,985.00 02/16/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150277
Principal investigator 1 Alnylam Pharmaceuticals Inc. $50.00 02/16/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150279
Principal investigator 1 Alnylam Pharmaceuticals Inc. $26.00 02/16/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150281
Principal investigator 1 Alnylam Pharmaceuticals Inc. $125.00 02/16/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150283
Principal investigator 1 Alnylam Pharmaceuticals Inc. $75.00 02/16/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150285
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 02/16/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150417
Principal investigator 1 Novo Nordisk AS $23.06 02/02/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1096869670
Principal investigator 1 Eli Lilly and Company $109.04 01/31/2024 Non-covered Recipient Entity
VIP TRIALS LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1137369746
Principal investigator 1 Eli Lilly and Company $775.83 01/31/2024 Non-covered Recipient Entity
VIP TRIALS LLC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1137370470
Principal investigator 1 Novo Nordisk AS $23.06 01/30/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1096871650
Principal investigator 1 Novo Nordisk AS $1,836.00 01/29/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4321 No dispute reported 06/30/2026 1096755136
Principal investigator 1 Novo Nordisk AS $426.60 01/29/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1096761946
Principal investigator 1 PFIZER INC. $618.05 01/25/2024 Non-covered Recipient Entity
VIP TRIALS LLC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1131048960
Principal investigator 1 Novo Nordisk AS $10,412.97 01/24/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
EX9536-4388 No dispute reported 06/30/2026 1096734007
Principal investigator 1 Novo Nordisk AS $2,250.00 01/24/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
EX9536-4388 No dispute reported 06/30/2026 1096820770
Principal investigator 1 Eli Lilly and Company $4,137.00 01/23/2024 Non-covered Recipient Entity
VIP TRIALS LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1137369278
Principal investigator 1 Eli Lilly and Company $28,299.00 01/23/2024 Non-covered Recipient Entity
VIP TRIALS LLC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1137369950
Principal investigator 1 Novo Nordisk AS $23.06 01/23/2024 Non-covered Recipient Entity
VICTORIUM CLINICAL RESEARCH LTD CO
NN9535-4352 No dispute reported 06/30/2026 1096846260
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,638.00 01/19/2024 Non-covered Recipient Entity
VIP Trials LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121150245